Oxygen and oxidative stress in bronchopulmonary dysplasia

Journal of Perinatal Medicine

Volumn 38, Issue 6, 2010, Pages 571-577

  Saugstad, Ola Didrik ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Bronchopulmonary dysplasia; Oxidative stress

Indexed keywords

8 ISOPROSTANE; ANTIOXIDANT; CATALASE; CCAAT ENHANCER BINDING PROTEIN; COPPER; GLUTATHIONE; GROWTH FACTOR; HYDROPEROXIDE; HYDROXYL RADICAL; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRON; LUNG SURFACTANT; MANGANESE; OXYGEN; PROTEIN P53; STAT PROTEIN; SUPEROXIDE DISMUTASE; THIOREDOXIN; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR NRF2; VASCULOTROPIN; ZINC;

DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; ENZYME ACTIVITY; GENE THERAPY; HUMAN; HYPEROXIA; INCIDENCE; INFLAMMATION; LUNG DYSPLASIA; MEDLINE; NONHUMAN; ONTOGENY; OXIDATIVE STRESS; OXYGEN SATURATION; OXYGEN THERAPY; PARENTERAL NUTRITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY DISTRESS SYNDROME; RESUSCITATION; REVIEW; STEM CELL;

ANTIOXIDANTS; BRONCHOPULMONARY DYSPLASIA; HUMANS; HYPEROXIA; INFANT, NEWBORN; INFANT, PREMATURE; OXIDATIVE STRESS; OXYGEN; TRANSCRIPTION FACTORS;

EID: 78650142009     PISSN: 03005577     EISSN: 16193997     Source Type: Journal    
DOI: 10.1515/JPM.2010.108     Document Type: Review

References (87)

1. Ahola T, Lapatto R, Raivio KO, Selander B, Stigson L, Jonsson B, et al. N-acetylcysteine does not prevent bronchopulmonary dysplasia in immature infants: a randomized controlled trial. J Pediatr. 2003;143:713-9. (Pubitemid 37510637)
2. Askie LM, Henderson-Smart DJ, Irwig L, Simpson JM. Oxygen-saturation targets and outcomes in extremely preterm infants. N Engl J Med. 2003;349:959-67. (Pubitemid 37064769)
3. Askie LM, Henderson-Smart DJ, Ko H. Restricted versus liberal oxygen exposure for preventing morbidity and mortality in preterm or low birth weight infants. Cochrane Database Syst Rev. 2009; (1): CD001077.
4. Auten RL, Davis JM. Oxygen toxicity and reactive oxygen species: the devil is in the details. Pediatr Res. 2009;66:121-7.
5. Babior BM, Kipnes RS, Curnutte JT. Biological defense mechanisms. The production by leukocytes of superoxide, a potential bactericidal agent. J Clin Invest. 1973;52:741-4.
6. Ballard PL, Truog WE, Merrill JD, Gow A, Posencheg M, Golombek SG, et al. Plasma biomarkers of oxidative stress: relationship to lung disease and inhaled nitric oxide therapy in premature infants. Pediatrics. 2008;121:555-61.
7. Bancalari E, Claure N. Definitions and diagnostic criteria for bronchopulmonary dysplasia. Semin Perinatol. 2006;30:164-70. (Pubitemid 44062673)
8. Banks BA, Ischiropoulos H, McClelland M, Ballard PL, Ballard RA. Plasma 3-nitrotyrosine is elevated in premature infants who develop bronchopulmonary dysplasia. Pediatrics. 1998;101:870-4. (Pubitemid 28204839)
9. Bhandari V. Hyperoxia-derived lung damage in preterm infants. Semin Fetal Neonatal Med. 2010 Apr. 27.
10. Bragt PC, Bonta IL. Oxidant stress during inflammation: antiinflammatory effects of antioxidants. Agents Actions. 1980;10:536-9. (Pubitemid 11181298)
11. Buonocore G, Zani S, Perrone S, Caciotti B, Bracci R. Intraerythrocyte non-protein-bound iron and plasma malondialdehyde in the hypoxic newborn. Free Radic Biol Med. 1998;25:766-70. (Pubitemid 28512528)
12. Buonocore G, Zani S, Sargentini I, Gioia D, Signorini C, Bracci R. Hypoxia-induced free iron release in the red cells of newborn infants. Acta Paediatr. 1998;87:77-81. (Pubitemid 28086610)
13. Campbell K. Intensive oxygen therapy as a possible cause of retrolental fibroplasia; a clinical approach. Med J Aust. 1951;2:48-50.
14. Cheah FC, Jobe AH, Moss TJ, Newnham JP, Kallapur SG. Oxidative stress in fetal lambs exposed to intra-amniotic endotoxin in a chorioamnionitis model. Pediatr Res. 2008;63:274-9. (Pubitemid 351301456)
15. Clerch LB, Wright AE, Coalson JJ. Lung manganese superoxide dismutase protein expression increases in the baboon model of bronchopulmonary dysplasia and is regulated at a posttranscriptional level. Pediatr Res. 1996;39:253-8. (Pubitemid 26039548)
16. Clyman RI, Saugstad OD, Mauray F. Reactive oxygen metabolites relax the lamb ductus arteriosus by stimulating prostaglandin production. Circ Res. 1989;64:1-8. (Pubitemid 19028498)
17. Coalson JJ. Pathology of new bronchopulmonary dysplasia. Semin Neonatol. 2003;8:73-81. (Pubitemid 36356495)
18. Das KC. Thioredoxin and its role in premature newborn biology. Antioxid Redox Signal. 2005;7:1740-3. (Pubitemid 41768005)
19. Davis JM, Parad RB, Michele T, Allred E, Price A, Rosenfeld W; North American Recombinant Human CuZnSOD Study Group. Pulmonary outcome at 1 year corrected age in premature infants treated at birth with recombinant human CuZn superoxide dismutase. Pediatrics. 2003;111:469-76. (Pubitemid 36330700)
20. Deulofeut R, Critz A, Adams-Chapman I, Sola A. Avoiding hyperoxia in infants < or = 1250 g is associated with improved short-and long-term outcomes. J Perinatol. 2006;26:700-5. (Pubitemid 44650189)
21. Dohlen G, Odland HH, Carlsen H, Blomhoff R, Thaulow E, Saugstad OD. Antioxidant activity in the newborn brain: a luciferase mouse model. Neonatology. 2008;93:125-31. (Pubitemid 351225342)
22. Ehrenkranz RA, Walsh MC, Vohr BR, Jobe AH, Wright LL, Fanaroff AA, et al. National Institutes of Child Health and Human Development Neonatal Research Network. Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. Pediatrics. 2005;116:1353-60. (Pubitemid 46056482)
23. Fellman V, Raivio KO. Reperfusion injury as the mechanism of brain damage after perinatal asphyxia. Pediatr Res. 1997;41:599-606. (Pubitemid 27183951)
24. Folkerth RD, Haynes RL, Borenstein NS, Belliveau RA, Trachtenberg F, Rosenberg PA, et al. Developmental lag in superoxide dismutases relative to other antioxidant enzymes in premyelinated human telencephalic white matter. J Neuropathol Exp Neurol. 2004;63:990-9. (Pubitemid 39202501)
25. 2-rich environment: the antioxidant enzymes in the developing rabbit lung. Pediatr Res. 1984;18:240-4. (Pubitemid 14166124)
26. Frank L, Lewis PL, Sosenko IR. Dexamethasone stimulation of fetal rat lung antioxidant enzyme activity in parallel with surfactant stimulation. Pediatrics. 1985;75:569-74. (Pubitemid 15144676)
27. Frank L, Sosenko IR. Prenatal development of lung antioxidant enzymes in four species. J Pediatr. 1987;110:106-10. (Pubitemid 17211894)
28. Frank L, Sosenko IR. Failure of premature rabbits to increase antioxidant enzymes during hyperoxic exposure: increased susceptibility to pulmonary oxygen toxicity compared with term rabbits. Pediatr Res. 1991;29:292-6.
29. Geary C, Caskey M, Fonseca R, Malloy M. Decreased incidence of bronchopulmonary dysplasia after early management changes, including surfactant and nasal continuous positive airway pressure treatment at delivery, lowered oxygen saturation goals, and early amino acid administration: a historical cohort study. Pediatrics. 2008;121:89-96.
30. Gerdin E, Tydén O, Eriksson UJ. The development of antioxidant enzymatic defense in the perinatal rat lung: activities of superoxide dismutase, glutathione peroxidase, and catalase. Pediatr Res. 1985;19:687-91. (Pubitemid 15006484)
31. Gerschman R, Gilbert D, Nye SW, Dwyer P, Fenn WO. Oxygen poisoning and X-irradiation: a mechanism in common. 1954. Nutrition. 2001;17:162.
32. Gordon HH, Demetry JP, Csapo G. Hemolysis in hydrogen peroxide of erythrocytes of premature infants: effect of alpha tocopherol. Am J Dis Child. 1952;84:472-4.
33. Groneck P, Götze-Speer B, Oppermann M, Eiffert H, Speer CP. Association of pulmonary inflammation and increased microvascular permeability during the development of bronchopulmonary dysplasia: a sequential analysis of inflammatory mediators in respiratory fluids of high-risk preterm neonates. Pediatrics. 1994;93:712-8. (Pubitemid 24136101)
34. Gross RT, Bracci R, Rudolph N, Schroeder E, Kochen JA. Hydrogen peroxide toxicity and detoxification in the erythrocytes of newborn infants. Blood. 1967;29:481-93.
35. Hallman M, Merritt TA, Schneider H, Epstein BL, Mannino F, Edwards DK, et al. Isolation of human surfactant from amniotic fluid and a pilot study of its efficacy in respiratory distress syndrome. Pediatrics. 1983;71:473-82. (Pubitemid 13116579)
36. Hayashibe H, Asayama K, Dobashi K, Kato K. Prenatal development of antioxidant enzymes in rat lung, kidney, and heart: marked increase in immunoreactive superoxide dismutases, glutathione peroxidase, and catalase in the kidney. Pediatr Res. 1990;27:472-5. (Pubitemid 20152796)
37. Haynes RL, Baud O, Li J, Kinney HC, Volpe JJ, Folkerth DR. Oxidative and nitrative injury in periventricular leukomalacia: a review. Brain Pathol. 2005;15:225-33. (Pubitemid 41161179)
38. Herting E, Speer CP, Harms K, Robertson B, Curstedt T, Halliday HL, et al. Factors influencing morbidity and mortality in infants with severe respiratory distress syndrome treated with single or multiple doses of a natural porcine surfactant. Biol Neonate. 1992;61(Suppl 1):26-30.
39. Kaarteenaho-Wiik R, Kinnula VL. Distribution of antioxidant enzymes in developing human lung, respiratory distress syndrome, and bronchopulmonary dysplasia. J Histochem Cytochem. 2004;52:1231-40. (Pubitemid 39097190)
40. Kontos HA, Wei EP, Povlishock JT, Christman CW. Oxygen radicals mediate the cerebral arteriolar dilation from arachidonate and bradykinin in cats. Circ Res. 1984;55:295-303. (Pubitemid 14047491)
41. Lane N. Oxygen. The molecule that made the world. Oxford: Oxford University Press; 2002.
42. Maltepe E, Saugstad OD. Oxygen in health and disease: regulation of oxygen homeostasis - clinical implications. Pediatr Res. 2009;65:261-8.
43. McCord JM. A superoxide-activated chemotactic factor and its role in the inflammatory process. Agents Actions. 1980;10:522-7.
44. Mercier JC, Olivier P, Loron G, Fontaine R, Maury L, Baud O. Inhaled nitric oxide to prevent bronchopulmonary dysplasia in preterm neonates. Semin Fetal Neonatal Med. 2009;14:28-34.
45. Merritt TA, Cochrane CG, Holcomb K, Bohl B, Hallman M, Strayer D, et al. Elastase and alpha 1-proteinase inhibitor activity in tracheal aspirates during respiratory distress syndrome. Role of inflammation in the pathogenesis of bronchopulmonary dysplasia. J Clin Invest. 1983;72:656-66. (Pubitemid 13051327)
46. Merritt TA, Deming DD, Boynton BR. The 'new' bronchopulmonary dysplasia: challenges and commentary. Semin Fetal Neonatal Med. 2009;14:345-57.
47. Morton RL, Das KC, Guo XL, Iklé DN, White CW. Effect of oxygen on lung superoxide dismutase activities in premature baboons with bronchopulmonary dysplasia. Am J Physiol. 1999;276: L64-74. (Pubitemid 29061666)
48. Noori S, Patel D, Friedlich P, Siassi B, Seri I, Ramanathan R. Effects of low oxygen saturation limits on the ductus arteriosus in extremely low birth weight infants. J Perinatol. 2009;29:553-7.
49. Northway WH Jr, Rosan RC. Radiographic features of pulmonary oxygen toxicity in the newborn: bronchopulmonary dysplasia. Radiology. 1968;91:49-58.
50. Northway WH Jr, Rosan RC, Porter DY. Pulmonary disease following respirator therapy of hyaline-membrane disease. Bronchopulmonary dysplasia. N Engl J Med. 1967;276:357-68.
51. Robinson KA, Stewart CA, Pye QN, Nguyen X, Kenney L, Salzman S, et al. Redox-sensitive protein phosphatase activity regulates the phosphorylation state of p38 protein kinase in primary astrocyte culture. J Neurosci Res. 1999;55:724-32. (Pubitemid 29173486)
52. Rosenfeld W, Evans H, Concepcion L, Jhaveri R, Schaeffer H, Friedman A. Prevention of bronchopulmonary dysplasia by administration of bovine superoxide dismutase in preterm infants with respiratory distress syndrome. J Pediatr. 1984;105:781-5. (Pubitemid 15206712)
53. Rubanyi GM, Vanhoutte PM. Oxygen-derived free radicals, endothelium, and responsiveness of vascular smooth muscle. Am J Physiol. 1986;250: H815-21.
54. Saugstad OD. Oxygen radicals and pulmonary damage. Pediatr Pulmonol. 1985;1:167-75.
55. Saugstad OD. Hypoxanthine as an indicator of hypoxia: its role in health and disease through free radical production. Pediatr Res. 1988;23:143-50. (Pubitemid 18095054)
56. Saugstad OD. Mechanisms of tissue injury by oxygen radicals: implications for neonatal disease. Acta Paediatr. 1996;85:1-4. (Pubitemid 26043198)
57. Saugstad OD. Update on oxygen radical disease in neonatology. Curr Opin Obstet Gynecol. 2001;13:147-53. (Pubitemid 32673545)
58. Saugstad OD. Oxidative stress in the newborn - a 30-year perspective. Biol Neonate. 2005;88:228-36. (Pubitemid 41433555)
59. Saugstad OD. Optimal oxygenation at birth and in the neonatal period. Neonatology. 2007;91:319-22. (Pubitemid 46934218)
60. Saugstad OD, Gluck L. Plasma hypoxanthine levels in newborn infants: a specific indicator of hypoxia. J Perinat Med. 1982;10:266-72. (Pubitemid 13177676)
61. Saugstad OD, Hallman M, Abraham JL, Epstein B, Cochrane C, Gluck L. Hypoxanthine and oxygen induced lung injury: a possible basic mechanism of tissue damage? Pediatr Res. 1984;18:501-4. (Pubitemid 14120024)
62. Saugstad OD, Sanderud J. Circulatory effects of oxygen radicals. Biomed Biochim Acta. 1989;48: S20-4.
63. See KC, Oei J, Lim CT, Clark R, Lui K, for the TO2RPIDO Multinational Study Group. Feasibility of Targeted Oxygen for the Resuscitation of Premature Infants and their Developmental Outcome (TO2RPIDO). PSZAN, 2009.
64. Sherlock R, Chessex P. Shielding parenteral nutrition from light: does the available evidence support a randomized, controlled trial? Pediatrics. 2009;123:1529-33.
65. Sosenko IR, Chen Y, Price LT, Frank L. Failure of premature rabbits to increase lung antioxidant enzyme activities after hyperoxic exposure: antioxidant enzyme gene expression and pharmacologic intervention with endotoxin and dexamethasone. Pediatr Res. 1995;37:469-75.
66. Sosenko IR, Jobe AH. Intraamniotic endotoxin increases lung antioxidant enzyme activity in preterm lambs. Pediatr Res. 2003;53:679-83. (Pubitemid 36406740)
67. Speer CP. Inflammation and bronchopulmonary dysplasia: a continuing story. Semin Fetal Neonatal Med. 2006;11:354-62. (Pubitemid 44038701)
68. Speer CP. Chorioamnionitis, postnatal factors and proinflammatory response in the pathogenetic sequence of bronchopulmonary dysplasia. Neonatology. 2009;95:353-61.
69. 2 levels and clinical outcome in ELBW infants on supplemental oxygen. PAS 2002, abstract 2033.
70. Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity (STOP-ROP), a randomized, controlled trial. I: primary outcomes. Pediatrics. 2000;105:295-310.
71. SUPPORT Study Group of the Eunice Kennedy Shriver NICHD Neonatal Research Network, Carlo WA, Finer NN, Walsh MC, Rich W, Gantz MG, Laptook AR, et al. Target ranges of oxygen saturation in extremely preterm infants. N Engl J Med. 2010;362:1959-69.
72. Suzuki YJ, Forman HJ, Sevanian A. Oxidants as stimulators of signal transduction. Free Radic Biol Med. 1997;22:269-85. (Pubitemid 26399334)
73. Tanswell AK, Freeman BA. Pulmonary antioxidant enzyme maturation in the fetal and neonatal rat. I. Developmental profiles. Pediatr Res. 1984;18:584-7. (Pubitemid 14086760)
74. Than NG, Romero R, Tarca AL, Draghici S, Erez O, Chaiworapongsa T, et al. Mitochondrial manganese superoxide dismutase mRNA expression in human chorioamniotic membranes and its association with labor, inflammation, and infection. J Matern Fetal Neonatal Med. 2009;22:1000-13.
75. Thébaud B, Abman SH. Bronchopulmonary dysplasia: where have all the vessels gone? Roles of angiogenic growth factors in chronic lung disease. Am J Respir Crit Care Med. 2007;175:978-85. (Pubitemid 46741748)
76. Thébaud B, Ladha F, Michelakis ED, Sawicka M, Thurston G, Eaton F, et al. Vascular endothelial growth factor gene therapy increases survival, promotes lung angiogenesis, and prevents alveolar damage in hyperoxia-induced lung injury: evidence that angiogenesis participates in alveolarization. Circulation. 2005;112:2477-86. (Pubitemid 41504498)
77. Tin W. Optimal oxygen saturation for preterm babies. Do we really know? Biol Neonate. 2004;85:319-25. (Pubitemid 38813011)
78. Tin W, Milligan DW, Pennefather P, Hey E. Pulse oximetry, severe retinopathy, and outcome at one year in babies of -28 weeks gestation. Arch Dis Child Fetal Neonatal Ed. 2001;84: F106-10. (Pubitemid 32250852)
79. van Haaften T, Byrne R, Bonnet S, Rochefort GY, Akabutu J, Bouchentouf M, et al. Airway delivery of mesenchymal stem cells prevents arrested alveolar growth in neonatal lung injury in rats. Am J Respir Crit Care Med. 2009;180:1131-42.
80. Van Marter LJ. Epidemiology of bronchopulmonary dysplasia. Semin Fetal Neonatal Med. 2009;14:358-66.
81. Vento M, Moro M, Escrig R, Arruza L, Villar G, Izquierdo I, et al. Preterm resuscitation with low oxygen causes less oxidative stress, inflammation, and chronic lung disease. Pediatrics. 2009.
82. Wagenaar GT, ter Horst SA, van Gastelen MA, Leijser LM, Mauad T, van der Velden PA, et al. Gene expression profile and histopathology of experimental bronchopulmonary dysplasia induced by prolonged oxidative stress. Free Radic Biol Med. 2004;36:782-801. (Pubitemid 38264421)
83. Walther FJ, David-Cu R, Mehta EI, Polk DH, Jobe AH, Ikegami M. Higher lung antioxidant enzyme activity persists after single dose of corticosteroids in preterm lambs. Am J Physiol. 1996;271: L187-91.
84. Watterberg KL, Demers LM, Scott SM, Murphy S. Chorioamnionitis and early lung inflammation in infants in whom bronchopulmonary dysplasia develops. Pediatrics. 1996;97:210-5. (Pubitemid 26049651)
85. Wedgwood S, Steinhorn RH, Bunderson M, Wilham J, Lakshminrusimha S, Brennan LA, et al. Increased hydrogen peroxide downregulates soluble guanylate cyclase in the lungs of lambs with persistent pulmonary hypertension of the newborn. Am J Physiol Lung Cell Mol Physiol. 2005;289: L660-6. (Pubitemid 41361676)
86. Welty SE. Is there a role for antioxidant therapy in bronchopulmonary dysplasia? J Nutr. 2001;13:947S-50S. (Pubitemid 32199176)
87. Wright CJ, Dennery PA. Manipulation of gene expression by oxygen: a primer from bedside to bench. Pediatr Res. 2009;66:3-10.